GSK Signs Copromotion Deal With Chinese Manufacturer For Influenza Vaccine
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Chinese vaccine manufacturer Sinovac Biotech will copromote its influenza vaccine Anflu with GlaxoSmithKline (China) Investment Co. under an exclusive service agreement announced Aug. 1
You may also be interested in...
Sinovac Beefs Up R&D To Bring Vaccines Into Clinical Trials To Prepare For Healthcare Reform
SHANGHAI - Chinese vaccine maker Sinovac said it will invest heavily in R&D over the next three years to prepare for China's ongoing healthcare reforms and to reduce the impact of the global financial crisis, during a conference call with investors and analysts on April 9
Sinovac Beefs Up R&D To Bring Vaccines Into Clinical Trials To Prepare For Healthcare Reform
SHANGHAI - Chinese vaccine maker Sinovac said it will invest heavily in R&D over the next three years to prepare for China's ongoing healthcare reforms and to reduce the impact of the global financial crisis, during a conference call with investors and analysts on April 9
Sinovac To Start Clinical Trials For Hep A Vaccine In Ukraine; First Overseas Steps
SHANGHAI - Sinovac has inked a deal with Ukraine-based Biolik Biopharmaceutical to conduct clinical trials for its inactivated hepatitis A vaccine Healive in Ukraine, the company announced on Sept. 15